Glycopyrronium (PT001) vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Glycopyrronium (PT001)
Developed by AstraZeneca
NCT03358147 · Phase 2/3 · completed
The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.
Next expected readout: May 2029 · NCT07525375 (registry estimate)
Reported efficacy
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)
Result source: NCT03358147
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT01573624 · Phase 2 · completed
The study randomized 421 participants to three 14-day treatment periods and kept participants and investigators blinded, with active comparator arms. Its primary outcomes were lung-function measures rather than hard clinical outcomes, and the results were mixed: trough FEV1 was significantly higher with the 125- and 250-mcg UMEC doses but not with the lower doses.
Reported efficacy
Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period); Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response by Dose of UMEC Combined With FF 100 mcg (Baseline (Day 1) and Day 15 of each treatment period); Mean Change From Baseline in Trough FEV1 on Day 15 of Each of the 3 Treatment Periods (Baseline (Day 1) and Day 15 of each treatment period): Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) (mixed)
Result source: NCT01573624
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Glycopyrronium (PT001) | Umeclidinium |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | —Trial running · NCT04651777 |
| Trough FEV1, change | 0.1 vs 0.1±0 vs placeboNCT033581472 other results
| 0.3 vs 0.1+0.2 vs placeboNCT0301206117 other results
|
| ACQ-5, change | -0.9 vs -0.9+0.1 vs placeboNCT033581472 other results
| —Trial running · NCT04651777 |
| OCS dose reduction | —Not reported | —Trial running · NCT04651777 |
Severe exacerbations, annualised rate
- Glycopyrronium (PT001)
- —Not reported
- Umeclidinium
- —Trial running · NCT04651777
Trough FEV1, change
- Glycopyrronium (PT001)
- 0.1 vs 0.1±0 vs placeboNCT03358147
2 other results
- 0.1 vs 0.1 NCT03358147
- 0.1 vs 0.1 NCT03358147
- Umeclidinium
- 0.3 vs 0.1+0.2 vs placeboNCT03012061
17 other results
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.3 vs 0.1 NCT03012061
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.1 NCT02164539
- 0.1 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.1 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.2 vs 0.1 NCT02164539
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
ACQ-5, change
- Glycopyrronium (PT001)
- -0.9 vs -0.9+0.1 vs placeboNCT03358147
2 other results
- -0.8 vs -0.9 NCT03358147
- -1.0 vs -0.9 NCT03358147
- Umeclidinium
- —Trial running · NCT04651777
OCS dose reduction
- Glycopyrronium (PT001)
- —Not reported
- Umeclidinium
- —Trial running · NCT04651777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Glycopyrronium (PT001): 4 of 4 rows · Umeclidinium: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Glycopyrronium (PT001) | Umeclidinium |
|---|---|---|
| Dropout rate | 14.5%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results16.3%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 14.2%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | —100 mcg + 125 mcga NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results—100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 5.9%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 2%31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 5.1%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 9.3%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 6.5%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 5.8%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 3.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 4.3%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 2.5%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 1.3%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results3.8%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.9%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | —100 mcg + 125 mcga NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results—100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 0%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy —100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 3.8%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results2.9%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.5%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | 0%100 mcg + 125 mcga NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results0%100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0.6%100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0.7%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 2.9%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 2.2%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 0.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 28.8 μg upper respiratory tract infection 6% (placebo 8%) nasopharyngitis 4.7% (placebo 3.4%) sinusitis 4.3% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results14.4 μg nasopharyngitis 6.3% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 2.9% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 7.2 μg nasopharyngitis 7.1% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 1.7% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | show 18 more results31.25 µg BID headache 4.5% (placebo 1.6%) nasopharyngitis 1.5% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 250 µg QD headache 4.4% (placebo 1.6%) product taste abnormal 3.7% (placebo 0%) nasopharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 125 µg QD headache 3.1% (placebo 1.6%) product taste abnormal 3.1% (placebo 0%) nasopharyngitis 2.3% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 62.5 µg QD headache 3.8% (placebo 1.6%) pharyngitis 3.8% (placebo 0.8%) nasopharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 31.5 µg QD headache 2.9% (placebo 1.6%) product taste abnormal 1.4% (placebo 0%) pharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 15.6 µg BID nasopharyngitis 3.2% (placebo 0.8%) headache 1.6% (placebo 1.6%) pharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 15.6 µg QD headache 3.8% (placebo 1.6%) nasopharyngitis 2.3% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 31.25 mcg QD nasopharyngitis 10.1% (placebo 11.9%) headache 6.5% (placebo 7.7%) upper respiratory tract infection 5.8% (placebo 2.1%) NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 62.5 mcg QD nasopharyngitis 9.4% (placebo 11.9%) headache 8.6% (placebo 7.7%) upper respiratory tract infection 4.3% (placebo 2.1%) NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 100/250 µg nasopharyngitis 1.9% toothache 0.5% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/125 µg dysphonia 6.5% nasopharyngitis 4.3% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/15.6 µg nasopharyngitis 7.1% toothache 7.1% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/62.5 µg nasopharyngitis 5% dysphonia 2.5% toothache 2.5% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/250/25 µg dysphonia 0% nasopharyngitis 0% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Glycopyrronium (PT001)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
Umeclidinium
show 4 more results
show 4 more results
show 4 more results
show 6 more results
show 6 more results
show 5 more results
show 3 more results
show 3 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrronium (PT001)'s landscape · Umeclidinium's landscape